Therefore, the applicability/usefulness of CK2 inhibitors in T-ALL patients should be further investigated, as the degree of response could be dependent on IKZF1 deletion and PI3K pathway alterations. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.